Abstract
Not only does COVID-19 pandemic encourage scientists to look for remedies and treatment schemes, but also identify the drivers of pathogenicity and spread of the virus.
The scope of this research consisted in identifying recurrence patterns and comparing the number of daily cases between various countries. Data for countries where at least 500 daily cases were recorded at least once (17 in Europe, 3 in North America, 7 in South America, 3 in Central America, 17 in Asia and 3 in Africa).
According to our evaluation, the dynamics recorded for 25 countries includes a 7-day statistically significant component. This statistically significant weekly component has been identified in 76% of the countries examined in Europe, 66% in North America, 71% in South America, and 18% in Asia. The range of this rhythmic component is low at the growth stage and increases at the stabilization and decrease stages.
The weekly phases feature shifting peaks depending on the country. In some cases, the phases shift, i.e. they are not limited strictly to certain days of the week. Due to range and phase variation, its explanation cannot be limited to strictly medical and social factors. In some cases, national incidence dynamics includes 3, 4, 6, 8 and 10-day periods.
Understanding the factors of recurrence patterns in COVID-19 incidence dynamics may help in the pandemic response.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
External funding was not received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB are needed
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data referred to in the manuscript are available
